Articles tagged with Drug Studies
A clinical trial shows that removing amyloid plaques from the brain can delay Alzheimer's symptoms, supporting the amyloid hypothesis. The treatment reduced the risk of developing dementia in people destined to develop early-onset Alzheimer's disease.
The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
The study found that tunneling nanotube-like structures connect cells in the heart, enabling long-distance intercellular communication essential for heart formation. Disruption of these structures resulted in impaired ventricular wall morphogenesis and defective myocardial growth.
A Phase 1 clinical trial is enrolling up to 55 healthy adults to test the safety and immunogenicity of a candidate Lassa vaccine. The trial aims to prevent Lassa fever, a viral hemorrhagic disease that can cause permanent hearing loss.
The ASCOLT trial found that aspirin does not statistically improve disease-free survival for all patients but demonstrates a consistent trend of improving overall and disease-free survival. Aspirin taken for up to 3 years is efficacious in patients with PIK3CA mutation, reducing recurrence by over 50%.
Researchers at NIH identified characteristic symptoms of topical steroid withdrawal (TSW), including elevated nicotinamide adenine dinucleotide (NAD+) levels, which can be diagnosed using provisional criteria. TSW treatment may involve mitochondrial complex I-blocking drugs, such as metformin or berberine.
Researchers have discovered a new diterpene-based drug that facilitates the repopulation of mature functional neurons in brain regions damaged by traumatic injuries. The study found that these new cells are integrated into neural circuits and develop functional characteristics similar to those eliminated by the injury.
Researchers found that mobile units with peer navigation improved health outcomes for participants with opioid use disorder, with about seven percent on medication and 35 percent virally suppressed. The study also showed lower odds of all-cause mortality in the intervention arm.
The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control. The antiviral drug was shown to be safe but ineffective in treating clade II mpox.
A major clinical trial has identified ensitrelvir as an effective medication to prevent symptomatic COVID-19 in people exposed within households. The trial showed a 67% reduction in risk of illness among participants taking the antiviral compared to those given a placebo.
Researchers are conducting a first-in-human clinical trial to test a modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder. The therapy, EG110A, aims to block sensory nerve signals causing involuntary bladder contractions and incontinence.
Scientists at Sanford Burnham Prebys discovered novel fragments of future drugs that selectively inhibit the enzyme VHR, which plays a role in controlling the immune system's response to danger. The findings may lead to the development of new therapies for sepsis and septic shock.
A new study found that Black Americans are more willing to participate in medical studies led by Black doctors and researchers. Diversifying clinical trial leadership could improve enrollment of underrepresented groups and ensure the benefits and risks of treatments are understood across populations.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
Eradivir's EV25 is a small molecule immunotherapy biotech company developing treatments for influenza. The Phase 2 challenge study will gather safety and efficacy data from healthy participants infected with influenza.
A new study analyzing health records from 2012 to 2022 found significant differences in cardiovascular disease risk factors among Asian American, Native Hawaiian, and Pacific Islander populations. The research suggests that regular monitoring of risk factors may help prevent cardiovascular disease among these groups.
Researchers are conducting a clinical trial to find the optimal combination of pain management tools for patients undergoing mastectomy procedures. The study will enroll approximately 100 patients and examine various combinations of pectoralis nerve blocks, non-opioid analgesics, and administration methods.
A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.
Researchers at the University of Missouri have identified a small molecule drug that targets a specific serotonin receptor, showing promise as a treatment for sarcopenia. The study suggests that this neurotherapeutic can improve muscle strength by activating motor neurons to fire more effectively.
The March issues of The American Journal of Psychiatry and Psychiatric Services bring together new developments in treating depression, obsessive-compulsive disorder, and schizophrenia. These journal publications highlight the latest advancements in digital mental health innovations.
The Texas Tech University Health Sciences Center is conducting a randomized controlled trial to investigate the effectiveness of calcium and vasopressin in treating severely injured patients who experience significant blood loss. The study, known as CAVALIER, will enroll approximately 1,050 participants aged 18-90.
A new study found that nearly 20% of cancer patients in middle-stage drug trials receive treatment that later gets FDA approval. This has important implications for drug development and clinical trial recruitment.
Researchers explore ataciguat to manage aortic valve stenosis, showing potential to significantly slow disease progression. The drug may enable a once-in-a-lifetime procedure by delaying valve replacement surgery.
US outpatient prescriptions for ivermectin and hydroxychloroquine increased significantly during the COVID-19 pandemic, with usage being three times higher among adults aged 65 and older. The study's findings highlight the need for policy reforms to combat misinformation and mistrust in scientific institutions.
Research found that community-dwelling older adults with advanced age, frailty, or multiple prescription medications had greater net benefits from intensive blood pressure lowering. However, this approach can increase treatment-related harms in these groups.
Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa, a group of rare and severe skin disorders. The licensing agreement includes collaboration with Theravia to develop, register and commercialise the drug.
A new study found that generic drugs made in India have significantly more 'severe adverse events' for patients, including hospitalization and death. The researchers matched 2,443 drugs made in the US and emerging economies, finding that mature generic drugs were responsible for the higher rates of severe adverse events.
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.
A study by University of Bath researchers found that stopping anticoagulants for patients aged 75 and over does not significantly affect the risk of major bleeding, but increases the risk of serious events like stroke and death. This highlights the need for clinicians to carefully consider the risks of stopping anticoagulation therapy ...
A new clinical trial will evaluate whether adding ketamine to standard treatment can improve outcomes for patients suffering from status epilepticus. The trial, called KESETT, hopes to determine whether ketamine can terminate the seizures in more patients than current treatments.
A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.
The Colorectal Cancer Alliance has awarded new grants to researchers, convened top scientists at the Cure CRC Summit, and launched K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. The initiative aims to improve outcomes for millions affected by the disease.
A clinical trial found that semaglutide significantly reduced weekly alcohol craving, drinking quantity, and the frequency of heavy drinking days in adults with symptoms of alcohol use disorder. Participants who received semaglutide also consumed lower amounts of alcohol during laboratory tests.
Researchers found that bimagrumab increases bone tissue while building muscle mass, reducing the risk of osteoporosis. The study suggests bimagrumab could be part of a second-generation weight loss drug on the market.
Researchers at Fujita Health University have developed a novel therapy using mesenchymal stem cells to treat inflammatory eye diseases, reducing inflammation and promoting tissue repair. The study found that adMSC injections effectively reduced inflammation in mice with GVHD without long-term complications.
Researchers at the University of Cincinnati presented studies on intracerebral hemorrhage treatment eligibility, finding only 3% of patients are eligible for a minimally invasive procedure. Additionally, a study found racial disparities in stroke recovery, with Black individuals experiencing worse functional outcomes after ischemic str...
The DISTAL trial found that endovascular therapy in addition to best medical therapy did not reduce disability more than clot-busting treatment alone for patients with medium distal vessel blockages. The study showed that mechanical clot removal was a safe option, but its benefits were uncertain.
A new study led by UCL researchers has found that the GLP-1 drug exenatide has no positive impact on movement, symptoms, or brain imaging in people with Parkinson's disease. The trial involved 194 participants and ran for 96 weeks, with no benefits shown in any of these areas.
A new drug developed by the Centre for Addiction and Mental Health (CAMH) has shown significant promise in reversing memory loss in a mouse model of Alzheimer's disease. The drug, GL-II-73, selectively targets GABA receptors to restore brain function and repair damaged neural connections.
Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.
A narrative review of over 1,700 papers found only seven papers addressing dexamphetamine addiction directly. The study raises questions about the evidence underpinning its restriction by regulatory agencies. Dexamphetamine is effective in treating ADHD and narcolepsy but may have benefits in treating obesity.
A new study from the University of Birmingham found that digoxin is more effective than beta-blockers in reducing adverse events and hospital admissions for older patients with atrial fibrillation. This could lead to significant cost savings for the UK National Health Service, estimated at £102 million per year.
A major clinical trial has identified three new safe and effective regimens for treating drug-resistant tuberculosis, offering faster, safer, and more accessible care. The new treatments show promise in reducing treatment duration and side effects, making them a significant breakthrough in the fight against this infectious disease.
A new compound, V-161, has been discovered to effectively inhibit the growth of vancomycin-resistant Enterococci (VRE) by targeting a crucial enzyme. The study reveals that V-161 not only disrupts the enzyme function but also reduces VRE colonization in the mouse small intestine.
Insilico Medicine has successfully dosed the first patient in its global Phase I clinical trial of ISM6331, a potent pan-TEAD inhibitor. The treatment demonstrates superior efficacy and safety in preclinical studies, with potential synergistic anti-tumor effects and overcoming drug resistance.
This study investigated the feasibility of electroacupuncture-assisted ribavirin dosing in patients with long COVID, using Voll's electropuncture diagnostics. The results demonstrated that EAV can identify meridians with decreased electrodermal activity at acupuncture points, followed by medicament testing to measure daily doses.
Researchers found associations between antibiotics, antivirals, vaccines, and anti-inflammatory drugs with reduced dementia risk. The study pooled data from over 130 million individuals, identifying potential repurposed treatments for dementia.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
A total of 105 compounds are identified from the SQ extract, with organic acids and amino acids dominating in the bloodstream. Pharmacokinetic profiles show dynamic changes in compound absorption and levels over time.
Researchers found that short-course antibiotics can be as effective as traditional longer treatments in preventing death and recurrence of pneumonia. This approach offers significant value for healthcare systems by reducing hospital expenditure while maintaining excellent patient outcomes.
This study investigates the biological mechanisms underlying incomplete immune reconstitution and evaluates Dihydroartemisinin's potential as a therapeutic agent. DHA effectively inhibits T cell activation in individuals with incomplete immune reconstitution, presenting a promising treatment strategy.
The study developed floating nanoballoons to improve ibuprofen's bioavailability and sustained release its anti-inflammatory effects. The formulation showed superior edema inhibition in acute inflammation studies, reducing TNF-α, hs-CRP, and IL-6 levels, while increasing anti-inflammatory IL-10 levels.
Researchers found that time in safe blood-sugar range can predict diabetes complications as accurately as hemoglobin A1c levels. The study used advanced machine learning techniques to analyze landmark diabetes data from the DCCT trial.
A clinical trial published in the New England Journal of Medicine showed that levofloxacin substantially reduced the risk of developing drug-resistant tuberculosis. The study found that levofloxacin reduced the risk of multidrug-resistant TB in adults and adolescents by 45 percent, and also significantly reduced the risk among family m...
Researchers found that carrots can enhance the body's ability to regulate blood sugar and positively influence the composition of gut bacteria. The study used mice with type 2 diabetes and found improved glucose tolerance after consuming carrot powder.
Research suggests ketamine use is increasing among US adults, linked to depression and sociodemographic factors. Expansion of prevention outreach and education on polydrug use harms are recommended.
Researchers have synthesized a molecule inspired by Nectandra leucantha and found it to be four times more potent than the prototype, killing Leishmania infantum selectively. The compound's bioavailability was improved, allowing it to circulate in the rat's organism for longer periods.
Researchers will analyze tissue samples from 100 patients over three years to understand why some respond better than others to biologic and targeted therapies. The study aims to improve matching of treatments to individual patients, reducing the guesswork and cost associated with ineffective treatment.
A recent case series suggests that an extended course of Paxlovid may help some patients with long Covid experience sustained improvements in their symptoms. The study, published in Communications Medicine, found that five out of 13 patients experienced significant symptom relief after taking the antiviral drug for 15 days.